The Experts below are selected from a list of 418575 Experts worldwide ranked by ideXlab platform
Xu-dong Yao - One of the best experts on this subject based on the ideXlab platform.
-
Advances in biomarkers for the Early Diagnosis of prostate cancer.
Chinese journal of cancer, 2010Co-Authors: Da-long Cao, Xu-dong YaoAbstract:More and more studies have revealed that the level of serum prostate specific antigen(PSA) has little value for Early Diagnosis of prostate cancer (PCa). For example, negative prostate biopsies are as high as 70%-80% for patients with serum PSA ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the Early Diagnosis of PCa, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives, HPC1, PCA3, TMPRSS2: ETS, GSTP1, AMACR, GOLPH2, EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the Early Diagnosis and the prognostic monitoring of patients with PCa.
Da-long Cao - One of the best experts on this subject based on the ideXlab platform.
-
Advances in biomarkers for the Early Diagnosis of prostate cancer.
Chinese journal of cancer, 2010Co-Authors: Da-long Cao, Xu-dong YaoAbstract:More and more studies have revealed that the level of serum prostate specific antigen(PSA) has little value for Early Diagnosis of prostate cancer (PCa). For example, negative prostate biopsies are as high as 70%-80% for patients with serum PSA ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the Early Diagnosis of PCa, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives, HPC1, PCA3, TMPRSS2: ETS, GSTP1, AMACR, GOLPH2, EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the Early Diagnosis and the prognostic monitoring of patients with PCa.
Kaihong Huang - One of the best experts on this subject based on the ideXlab platform.
-
New developments in the Early Diagnosis of pancreatic cancer
Expert review of gastroenterology & hepatology, 2016Co-Authors: Qiubo Zhang, Shaojie Chen, Linjuan Zeng, Yinting Chen, Guoda Lian, Chenchen Qian, Ruijie Xie, Kaihong HuangAbstract:ABSTRACTIntroduction: Pancreatic cancer is an aggressive carcinoma of the digestive system and radical resection, which is available to very few patients, is the only possibility for cure. Since therapeutic choices are limited at the advanced stage, screening and Early diagnostic tools are indispensable for a better prognosis.Areas covered: This review illustrates serologic and imaging examinations, and carbohydrate antigens, microRNAs, methylation biomarkers, molecules in exosomes, ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography and endoscopic retrograde cholangiopancreatography, among other topics. No matter which approach is used, the accuracy of Early Diagnosis is extremely low. Combining different methods greatly improves the accuracy of Early Diagnosis. This review was conducted utilizing PubMed with key search words pancreatic cancer, Early Diagnosis, biomarkers and imaging.Expert commentary: Appropriate combination of biomarkers and imaging technologies wi...
Nina Einhorn - One of the best experts on this subject based on the ideXlab platform.
-
Early Diagnosis and screening
Hematology oncology clinics of North America, 1992Co-Authors: Nina EinhornAbstract:Late Diagnosis is the main reason for the poor outcome of ovarian cancer patients. An attempt to diagnose the disease methods for Early Diagnosis was recently investigated. The main effort of the study was in finding the role of ultrasonography and CA-125 and their sensitivity and specificity in the screening procedure. The preliminary reports suggest that a mortality study with a large women population has to be done before the usefulness of screening these methods can be established.
Qiubo Zhang - One of the best experts on this subject based on the ideXlab platform.
-
New developments in the Early Diagnosis of pancreatic cancer
Expert review of gastroenterology & hepatology, 2016Co-Authors: Qiubo Zhang, Shaojie Chen, Linjuan Zeng, Yinting Chen, Guoda Lian, Chenchen Qian, Ruijie Xie, Kaihong HuangAbstract:ABSTRACTIntroduction: Pancreatic cancer is an aggressive carcinoma of the digestive system and radical resection, which is available to very few patients, is the only possibility for cure. Since therapeutic choices are limited at the advanced stage, screening and Early diagnostic tools are indispensable for a better prognosis.Areas covered: This review illustrates serologic and imaging examinations, and carbohydrate antigens, microRNAs, methylation biomarkers, molecules in exosomes, ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography and endoscopic retrograde cholangiopancreatography, among other topics. No matter which approach is used, the accuracy of Early Diagnosis is extremely low. Combining different methods greatly improves the accuracy of Early Diagnosis. This review was conducted utilizing PubMed with key search words pancreatic cancer, Early Diagnosis, biomarkers and imaging.Expert commentary: Appropriate combination of biomarkers and imaging technologies wi...
